Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.40 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | UGCG | Q16739 | 2/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | OSBP | P22059 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24141990 | 0.97 | POLA1 (0.45) | POLA1PLA2G2ACYP46A1APPNR1H3 | |
| SCHEMBL15849326 | 0.97 | POLA1 (0.45) | POLA1PLA2G2ACYP46A1APPNR1H3 | |
| SCHEMBL4546174 | 0.97 | POLA1 (0.45) | POLA1PLA2G2ACYP46A1APPNR1H3 | |
| SCHEMBL837589 | 0.96 | POLA1 (0.45) | POLA1PLA2G2ACYP46A1APPNR1H3 | |
| SCHEMBL15186906 | 0.94 | POLA1 (0.45) | POLA1PLA2G2ACYP46A1APPNR1H3 | |
| SCHEMBL19272838 | 0.93 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1APPNR1H3 | |
| SCHEMBL13556705 | 0.93 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1APPNR1H3 | |
| SCHEMBL4546173 | 0.93 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1APPNR1H3 | |
| SCHEMBL19152812 | 0.93 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1APPNR1H3 | |
| SCHEMBL14652823 | 0.93 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1APPNR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20180216115-A1 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene | BANK OF AMERICA, N.A. | 2018-08-02 | — | — | US | disclosed |
| US-20180171332-A1 | siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis | ALNYLAM PHARMACEUTICALS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180127749-A1 | Compositions and Methods for Inhibiting Expression of Factor V | BANK OF AMERICA, N.A. | 2018-05-10 | — | — | US | disclosed |
| US-9963700-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9957507-B2 | Compositions and methods for inhibiting expression of mutant EGFR gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9868950-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9822365-B2 | Compositions and methods for inhibiting expression of the PCSK9 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170321213-A1 | Compositions and Methods for Inhibiting Expression of Transthyretin | BANK OF AMERICA, N.A. | 2017-11-09 | — | — | US | disclosed |
| US-20110124711-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Nav1.8 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110112178-A1 | Compositions And Methods For Inhibiting Expression Of IKK-B Gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110105590-A1 | Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes | VORNLOCHER HANS-PETER | 2011-05-05 | — | — | US | disclosed |
| US-20110071209-A1 | RNAi Modulation of the RHO-A Gene and Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110060031-A1 | Compositions And Methods For Inhibiting Expression Of A Gene From The Ebola Virus | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110034537-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD45 GENE | BANK OF AMERICA, N.A. | 2011-02-10 | — | — | US | disclosed |
| US-20110015250-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE | ALNYLAM PHARMACEUTICALS, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110015252-A1 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE | BANK OF AMERICA, N.A. | 2011-01-20 | — | — | US | disclosed |
| US-20110003882-A1 | RNAi Modulation of AHA and Therapeutic Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100003317-A1 | COMPOSITIONS AND METHODS FOR MEDIATING RNAI IN VIVO | BANK OF AMERICA, N.A. | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180171332-A1 | siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis | TTR, CRYAA, SARNP | POLA1 917/4885PLA2G2A 3424/4885CYP46A1 1935/4885 |
| US-20110034537-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD45 GENE | PTPRC, PTPRCAP, DDX21 | POLA1 414/4885PLA2G2A 606/4885CYP46A1 2057/4885 |
| US-20110060031-A1 | Compositions And Methods For Inhibiting Expression Of A Gene From The Ebola Virus | EIF2AK2, DDX39B, STING1 | POLA1 741/4885PLA2G2A 2190/4885CYP46A1 4391/4885 |
| US-20110112178-A1 | Compositions And Methods For Inhibiting Expression Of IKK-B Gene | IKBKG, IKBKB, NFKBIA | POLA1 232/4885PLA2G2A 1279/4885CYP46A1 3134/4885 |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | GNAQ, GNAI1, GNAI2 | POLA1 657/4885PLA2G2A 195/4885CYP46A1 3979/4885 |
| US-20100003317-A1 | COMPOSITIONS AND METHODS FOR MEDIATING RNAI IN VIVO | FABP3, MYLK2, TNNC1 | POLA1 616/4885PLA2G2A 96/4885CYP46A1 1697/4885 |
| US-20180216115-A1 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene | PCSK9, PCSK7, RNASE1 | POLA1 326/4885PLA2G2A 493/4885CYP46A1 80/4885 |
| US-20110071209-A1 | RNAi Modulation of the RHO-A Gene and Uses Thereof | RHOA, ARHGDIA, RHOC | POLA1 2746/4885PLA2G2A 407/4885CYP46A1 1564/4885 |
| US-20110015250-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE | GEMIN5, KIF5A, KIF5C | POLA1 507/4885PLA2G2A 1517/4885CYP46A1 2524/4885 |
| US-20110124711-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Nav1.8 GENE | SCN8A, SCN7A, SCN1A | POLA1 1179/4885PLA2G2A 899/4885CYP46A1 4264/4885 |
| US-20110015252-A1 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE | PCSK9, PCSK7, PCSK6 | POLA1 727/4885PLA2G2A 273/4885CYP46A1 60/4885 |
| US-20170321213-A1 | Compositions and Methods for Inhibiting Expression of Transthyretin | TTR, RNGTT, RNASE1 | POLA1 662/4885PLA2G2A 2597/4885CYP46A1 847/4885 |
| US-20110105590-A1 | Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes | BCL2, BAK1, BBC3 | POLA1 509/4885PLA2G2A 468/4885CYP46A1 4310/4885 |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | TTR, CRYAA, SARNP | POLA1 917/4885PLA2G2A 3424/4885CYP46A1 1935/4885 |
| US-20180127749-A1 | Compositions and Methods for Inhibiting Expression of Factor V | F5, F13B, F13A1 | POLA1 607/4885PLA2G2A 553/4885CYP46A1 1847/4885 |
| US-20110003882-A1 | RNAi Modulation of AHA and Therapeutic Uses Thereof | AHSA1, MTREX, RNASEH1 | POLA1 1318/4885PLA2G2A 1447/4885CYP46A1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.